NIH Study Explains Why GLP-1 Weight Loss Plateaus Happen

NIH researchers used fluorescence imaging to observe how GLP-1 drugs affect individual brain neurons.

A Cellular Explanation for Weight Loss Stalls

For the millions of people taking GLP-1 receptor agonists like semaglutide, a common frustration has been the eventual slowdown — or complete stop — of weight loss after months of steady progress. Now, a study published in Nature Metabolism on May 22, 2026, by researchers at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the NIH, offers a biological explanation for why these plateaus occur.

Using real-time fluorescence imaging in mouse brain tissue, the researchers observed for the first time how GLP-1 drugs behave inside individual appetite-regulating neurons. Their findings suggest that the problem may lie not with the drug itself, but with how certain brain cells respond to it over time.

How GLP-1 Drugs Signal in the Brain

According to the NIH study, GLP-1 receptor agonists work in part by increasing levels of a signaling molecule called cyclic adenosine monophosphate (cAMP) inside neurons located in the area postrema — a hindbrain region that plays a key role in appetite regulation and the sensation of fullness.

However, the researchers found that this cAMP response is not uniform. Instead, neurons fell along a continuum of responses:

• Sustained responders: Some neurons maintained elevated cAMP levels over extended periods, suggesting ongoing appetite-suppressing signaling
• Transient responders: Other neurons experienced only brief spikes in cAMP before the signal faded, even while the drug was still present

According to the study authors, the transient responders appear to be internalizing or degrading their own GLP-1 receptors, effectively pulling the drug's docking sites from the cell surface and shutting down the signaling pathway prematurely.

Receptor Internalization: The Plateau Mechanism

This process of receptor internalization, as described by the NIH researchers, means that even when a patient continues taking their GLP-1 medication at the same dose, the brain cells responsible for suppressing appetite may progressively lose their ability to respond. The "fullness" signal weakens — not because the drug stopped working, but because the cellular machinery that receives the signal has been withdrawn.

As reported by ScienceDaily and Neuroscience News, this finding provides one of the first mechanistic explanations for the clinical observation that many patients on GLP-1 therapies experience diminishing weight loss returns after an initial period of strong efficacy. For patients exploring treatment options, understanding this biology may help contextualize discussions with their healthcare providers about adjusting their approach.

Roflumilast: A Potential Fix for Fading Signals

Perhaps the most compelling finding from the study involves a potential solution. The researchers tested roflumilast, an FDA-approved drug currently used to treat chronic obstructive pulmonary disease (COPD), which works by inhibiting an enzyme called phosphodiesterase 4 (PDE4).

PDE4 is responsible for breaking down cAMP inside cells. According to the study, when the researchers applied roflumilast to the brain tissue, it blocked PDE4 from degrading cAMP, effectively converting transient-responding neurons into sustained responders. In other words, the drug appeared to restore the appetite-suppressing signal in cells that had previously gone silent.

The researchers emphasized several important caveats:

• This was a mechanistic study conducted in mouse brain tissue, not a clinical trial in humans
• Roflumilast's use as a GLP-1 plateau intervention is entirely experimental
• Combining roflumilast with GLP-1 drugs would require rigorous clinical testing before any therapeutic application

What This Means for GLP-1 Patients

While this research is still in early stages, it opens new avenues for understanding and potentially addressing one of the most common challenges facing patients on medications like semaglutide and tirzepatide. The identification of PDE4 inhibition as a mechanism for sustaining drug signaling could, according to the researchers, eventually inform combination therapy strategies.

For individuals currently experiencing a weight loss plateau on GLP-1 therapy, the NIH team's work suggests this is a biological phenomenon — not a failure of willpower or effort. Anyone with concerns about their treatment progress should speak with a qualified healthcare provider about their individual situation.

This article is for informational purposes only and is not medical advice. Consult your healthcare provider before starting any weight loss medication or treatment.